Alnylam Pharmace. buy DropStone
Start price
03.11.20
/
50%
€111.28
Target price
04.11.21
-
Performance (%)
-6.56%
End price
06.01.21
€103.98
Summary
This prediction ended on 06.01.21 with a price of €103.98. With a performance of -6.56%, the BUY prediction for Alnylam Pharmace. by DropStone closed slightly in the red. DropStone has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 1.593% | 1.593% | 45.419% | 50.100% |
| iShares Core DAX® | 0.765% | 4.791% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 1.418% | 3.133% | 5.422% | 113.046% |
| iShares Nikkei 225® | 0.658% | 0.972% | 15.333% | 47.267% |
| iShares S&P 500 | 1.310% | 2.279% | 3.125% | 68.687% |
Comments by DropStone for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.